References
Ayata C: Spreading depression: from serendipity to targeted therapy in migraine prophylaxis. Cephalalgia 2009, 29(10):1095–1114.
Tvedskov JF, Iversen HK, Olesen J: A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine. Cephalalgia 2004, 24(10):875–882.
Ayata C, Jin H, Kudo C, et al.: Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006, 59(4):652–661.
Goadsby PJ, Ferrari MD, Csanyi A, et al.: Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 2009, 29(7):742–750.
Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24(Suppl 1):9–160.
Bigal ME, Lipton RB: The epidemiology, burden, and comorbidities of migraine. Neurol Clin 2009, 27(2):321–334.
Kruit M, van Buchem M, Launer L, et al.: Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia 2009 Jun 8 (Epub ahead of print).
Scher AI, Gudmundsson LS, Sigurdsson S, et al.: Migraine headache in middle age and late-life brain infarcts. JAMA 2009, 301(24):2563–2570.
Disclosure
No potential conflict of interest relevant to this article was reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Garza, I. Tonabersat: A Cortical Spreading Depression Inhibitor as Potential Pharmacologic Prophylaxis in Migraine with Aura. Curr Neurol Neurosci Rep 10, 7–9 (2010). https://doi.org/10.1007/s11910-009-0083-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11910-009-0083-9